Shreya Life Sciences: Russia Operations Status & Business Impact
LeaveRussia detail: Continue Operations
Shreya Life Sciences Private Limited distributes pharmaceutical products. The Company markets antibiotics, antiinfectives, ophthalmologicals, pain management, surgical, and diabetic rage products.
Decision trail
Decision date 27/10/2024 · Reference ↗
Mumbai pharma company Shreya helping Russia get Nvidia AI chips. Exports by Shreya to Russia "perfectly" legal.
Status history since 2022
- 03/08/2026 — operating · Imported from KSE LeaveRussia
Possible sanctions matches
Name-based matches against EU/US/UK lists — verify identity before drawing conclusions.
Exposure profile
Get alerts if this company's Russia status changes
7-day Pro trial includes watchlists for companies you track. No credit card. Full exposure maps are on Professional after the trial.
Start 7-day Pro trialGeopolitical context and sanctions impact
Shreya Life Sciences is a Pharma & Healthcare company based in India. Current Russia status in our dataset is operating: continued operations in Russia remain a compliance, reputational and counterparties risk for EU and allied firms. Eastern Europe Impact translates those facts into business consequences — sanctions screening, supply-chain exposure and reconstruction-side opportunity — with transparent confidence labels rather than speculation.
Risk assessment and how to use this profile
Start with the status badge and decision trail, then check possible sanctions matches and recent events mentioning Shreya Life Sciences. A 7-day Pro trial adds watchlists so you are notified if Russia status, designations or linked events change. Full exposure maps (energy, transport, commodities) are on Professional. This page is risk information, not legal or investment advice.
Questions about Shreya Life Sciences
What kind of data does Eastern Europe Impact provide on Shreya Life Sciences?
- Eastern Europe Impact publishes verified intelligence on Shreya Life Sciences's Russia status: current operating posture, sources (including the KSE LeaveRussia project), status history since 2022, sanctions-list matches, and linked events. Each profile is risk information for compliance and due diligence — not legal advice.
How can Eastern Europe Impact data on Shreya Life Sciences help my business?
- Use the Shreya Life Sciences profile to check counterparties, suppliers and customers for Russia exposure, sanctions proximity and recent events before you contract, ship or invest. Watchlists alert you if the status or designations change.
How do we verify the information on Shreya Life Sciences?
- We compile public reporting, company statements and the KSE LeaveRussia dataset, then label uncertainty. Status is not a legal determination — verify against primary filings and counsel before acting. Corrections go to corrections@easterneuropeimpact.com.
How much does Eastern Europe Impact cost?
- The company checker is free. A 7-day Pro trial (no credit card) unlocks live Daily Impact Briefs, full event profiles and watchlists. After the trial, Individual is €19/month; Professional and Business add exposure maps, sanctions entity pages and API access. See /pricing.